Introduction
The human papillomavirus (HPV) infects an estimated 6.2 million people in the United States every year, and is the most common sexually transmitted infection.
1 Persistent infection with high-risk HPV serotypes, particularly types 16 and 18, is the most important risk factor for developing cervical cancer 1 while infection with HPV types 6 and 11 is responsible for most genital wart cases. 1 The quadrivalent HPV vaccine (Gardasil®) is designed to prevent anogenital disease and cervical cancer associated with HPV types 6, 11, 16, and 18. 2 Since HPV is such a common sexually transmitted infection, the HPV vaccine is most effective when administered prior to sexual debut. 3 American Academy of Pediatrics and the American Academy of Family Practitioners also espouse similar recommendations. 4 In October of 2009, the ACIP updated its recommendations about HPV vaccination. [5] [6] The bivalent vaccine was also approved for use in females 9-26 years of age, 5 and the quadrivalent vaccine was approved for use in males 9-26 years of age in order to prevent anogenital warts. 6 Nevertheless, the focus of this report is on the use of the vaccine in women, specifically the quadrivalent product, given the relatively recent introduction of the bivalent vaccine and use of the quadrivalent vaccine in males.
Despite the federal government's approval of the vaccine, its recommendation to vaccinate females from 9-26 years of age, 1 and its addition of Gardasil® to the Vaccines for Children Program, 7 the reported rates of HPV vaccination for young girls remains low. Nationally, only 37 .2% of adolescent females (aged 13-17) had initiated the HPV vaccine series in 2008, and only 17.9% of females had received all 3 doses. 8 The clinical trials demonstrating the effectiveness of the vaccine against cervical cancer and genital warts had high rates of compliance, 9 and thus the effectiveness of the vaccine in girls who do not complete the series is unknown.
The quadrivalent vaccine is recommended to be administered as 3 separate doses with the 2 nd and 3 rd dose given at 2 and 6 months following the first dose, respectively. In clinical practice, it is likely that some females will receive their 2 nd and 3 rd vaccine doses at intervals outside the recommended dosing window. [10] [11] [12] Currently, the standard of care is to finish the three-doses regardless of the schedule. 1 There are limited data to assess how the late timing of the intervals between the 1 st and 2 nd or 2 nd and 3 rd dose of the vaccine will affect the humoral immune response, but studies are currently underway.
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To our knowledge, no systematic reviews about the uptake, completion, and adherence to dosing schedules of the HPV vaccine exist in the literature. Few studies have examined correlates for completion of the HPV vaccination series. [17] [18] [19] However, we are aware of no study documenting factors associated with on-time dosing in addition to vaccine series completion.
This report is a new systematic review of the current state of the literature on the subject. The review focuses on the completion rates of the HPV vaccine and on factors that are associated with series uptake or completion. The goal of this review is to highlight the extent to which the HPV vaccine is being completed when initiated, along with the factors associated with completion and uptake. This information will give insight into ways physicians, public health professionals, and policymakers can act in order to address the problems of low uptake and poor completion rates. Low uptake may reduce vaccine's impact on the population to prevent cervical cancer, while poor completion rates may reduce the effectiveness of the vaccine against cervical cancer and anogenital disease.
In order to answer the question about actual uptake and completion of the HPV vaccine, we sought observational studies characterizing HPV vaccination rates (uptake or completion) and factors associated with vaccination in women between the ages of 9-26. Clinical trials were not chosen in this review due to the fact that trial settings have inflated adherence rates, and the goals of this review were to determine actual HPV vaccination rates in various real-world practice settings, as well as to determine socioeconomic and other demographic factors associated with these rates.
Methods

Eligibility Criteria:
Studies which included women living in the United States who were also between the ages of 9-26 (or any group within that range) were eligible for review. All observational study designs (cross-sectional, retrospective cohort, and prospective cohort) were eligible. Given the paucity of data, since the vaccine is relatively new, information from published abstracts without a corresponding published manuscript were also included. All controlled trials (randomized and non-randomized) that measured the effectiveness of an intervention program were excluded from the review in order to assess the completion rates of the HPV vaccination in a real-world clinical setting rather than in an experimental situation. Included studies had to have the primary outcome as the rate of vaccine uptake or vaccine completion. Studies examining socioeconomic and demographic factors associated with vaccine utilization were also included. Studies examining factors for vaccination acceptance (intention to receive the vaccine or openness to receiving the vaccine) were excluded from analysis due to the fact that acceptance and actual vaccine uptake are different outcomes that have different factors associated with them. Studies were limited to English speaking articles from 2006 until March 2010. This date range includes all studies since the FDA approval of the HPV quadrivalent vaccine, which was necessary for widespread dissemination and acceptance of the vaccine.
Information Sources:
We conducted literature searches using PubMed (2006-present) and Google Scholar (2006 -present). Limits on both databases were set to English language articles published after 2006.
The last search was run on March 8, 2010 . In addition to database searching, studies were identified through the cross-checking of reference lists of the selected articles.
Search Strategy:
Search terms included the following MeSH terms in PubMed: Papillomavirus vaccines, vaccination statistics and numerical data, vaccination administration and dosage, vaccination trends, vaccination utilization, and immunization schedule. The following keywords were also used in both PubMed and Google Scholar: HPV vaccination rates, HPV vaccination uptake, delayed dosing vaccine, completion rates, timeliness, and completion.
The search strategy conducted using PubMed is shown below: 
Study Selection:
After the database searches, studies were screened based on relevant titles by the author (WT) in an unblinded manner. Eligible studies were then identified using abstracts to further narrow the selection to articles relevant to HPV vaccine uptake, series completion, and factors associated with both uptake and completion. Studies were excluded if they were not written in English, were clinical trials, or had a study population not based in the United States. The remaining articles were then fully reviewed by the author (WT).
Each stage of the study selection (screening, eligibility criteria, and full text review) was conducted by one author (WT) in an unblinded fashion. If the author had any concerns regarding the eligibility or relevancy of a study, he discussed the study with an expert methodologist (AV) and physician (EBW) who is an expert in the field of vaccines.
Data Collection:
The data from each study included in the full-text review were extracted using a standardized form based on a critical appraisal form that has been pilot tested and used in a graduate-level literature appraisal course at the UNC Gillings School of Global Public Health. I extracted the information from all the studies included in the full-text review.
The information extracted from each trial included: author, title, study year, study design/type, length of follow-up, source population, main results, study strengths, study weaknesses (biases), generalizability, conclusion, and overall study quality.
Data Quality:
When assessing risk of bias in individual studies, the author examined the risk of selection bias (patient selection, inclusion/exclusion criteria, loss to follow-up, dropouts), measurement bias (equal measurement methods, valid data collection methods, reliable tools), and confounding bias (statistical adjustments) in order to determine the quality and reliability of each study's results. Outcome level biases were not assessed given the paucity of data and heterogeneity between study populations and outcome measures.
The quality of each fully reviewed article was evaluated using an appraisal scheme based on USPSTF guidelines. Each article was graded based on its strength of study design, risk of bias, implementation, and generalizability of results. The article was then assigned a grade of poor, fair, or good. Since there are so few studies examining the completion rates of HPV vaccination and factors associated with uptake or series completion, poor quality studies were included in the review.
When reporting outcomes measures, the studies investigating vaccine uptake and series completion summarized rates in terms of percentages. The factors associated with uptake and completion were reported using either odds ratios or adjusted risk ratios.
The potential for publication bias or selective reporting is low as these are observational studies with results that would be informative regardless of the findings. Selective reporting of data might be a problem, but the methods and results were reviewed for each study to detect any discrepancy between stated design and reporting of the actual outcomes.
Results
Study Selection:
A total of 14 studies were identified for inclusion in the review (Figure) . The initial literature search yielded 530 article citations. Based on the title alone, 390 articles were excluded as irrelevant. After reviewing the abstracts and excluding studies based on previously described criteria, such as experimental trials and studies about vaccine acceptability, 12 articles were identified for a full review. An additional two articles that fit eligibility criteria were identified by checking references of the 12 articles identified through the literature search. Of the 14 total studies included in the systematic review, one was an abstract that had no corresponding published full manuscript. 
Flow Diagram about Search Strategy
Study Characteristics:
The 14 studies were all observational reports published in English within the past four years.
All the studies were based in the United States. Three of the studies 17, [20] [21] were prospective cohort in design, three were retrospective cohort studies, [18] [19] 22 and eight were cross-sectional studies. [23] [24] [25] [26] [27] [28] [29] [30] The prospective and retrospective cohort studies had follow-up periods ranging from 6 to 24 months with 5 out of 6 of these studies having follow-up periods lasting at least 12 months. [17] [18] [19] [20] 22 The cross-sectional studies sampled their respective study populations between
October of 2006 and November of 2008, and four studies sampled between May and October of 2007. [23] [24] [25] 27 The study populations for all 14 studies varied greatly; for example, some studies sampled from a large, managed care organization like Kaiser Permanente while another study used a small set of urban pediatric practices affiliated with one academic institution.
The cohort studies (both retrospective and prospective) enrolled females between the ages of 9 and 26 years, 17, 20 but some studies focused more on adolescents (9-18 years old) 19, 22 while others focused on young women (13-26 years old). 21 These studies obtained their study population from a large managed care organization (Kaiser Permanente), 17, 20, 22 an urban hospital-based teen health center, 21 and university-based outpatient clinics. [18] [19] The crosssectional studies surveyed females between the ages of 11 and 26 years of age, [24] [25] [26] [27] [29] [30] as well as parents of females aged 9 to 18 years. 23, 28 Four studies used a nationally representative sample for their surveys, [23] [24] [29] [30] while four studies surveyed females from a specific area, such as two universities 26 or five urban pediatric practices. 27 Depending on the study in question, the outcomes addressed were either HPV vaccine initiation rates, HPV vaccine completion rates, or both. Three of the 14 articles concentrated on initiation rates of the HPV vaccine, 20, 24, 27 two focused on completion rates, [17] [18] and six addressed both. 19, 21-22, 25-26, 30 The other three articles did not explicitly look at initiation or completion rates, but only at factors associated with vaccine uptake or series completion. 23, [28] [29] Factors associated with either vaccine initiation or completion were discussed in all cohort studies [17] [18] [19] [20] [21] [22] and in five of the eight cross-sectional studies. 24, 26, [28] [29] [30] One cross-sectional study discussed factors associated with acceptance of a hypothetical 3-shot vaccine, 23 another discussed factors associated with intent to vaccinate, 25 while a third study did not discuss the subject. 27 Please refer to Table 1 for a comprehensive review of the study characteristics. 
Outcome Results of Individual Studies:
The results of each individual study are shown in the table below. 
Synthesis of Results:
The study designs, participants, reported outcomes, and measured factors associated with the outcomes varied markedly for all of the 14 studies in this review, and therefore results are synthesized qualitatively rather than through a meta-analysis.
The results of the review show a wide range of initiation rates for the HPV vaccine varied between 5% and 77% (9 studies), with the majority of studies falling between 25% and 45% (6 studies). The completion rates of the vaccine varied between 0.2% and 58.2% (8 studies), with the majority of studies falling between 40% and 50% (4 studies). Three studies reported on-time dosing, but did not further describe factors associated with the finding. There was wide variability in the results, as demonstrated by the range of 1.5% to 72% for women receiving the vaccine in a delayed fashion.
In terms of factors associated with uptake, the studies varied in which correlates they decided to choose, the statistical methods in which they analyzed these factors, and also in the populations in which these correlates applied. Therefore, while it is difficult to combine the results, a few trends emerged. is also unclear -one study reported that having insurance compared to no insurance is predictive of vaccination initiation, but another found that public insurance was better than private in terms of initiation rates.
In terms of factors associated with completion, the results were also difficult to synthesize given the same reasons highlighted above for the factors associated with vaccine initiation.
Nevertheless, there are still a few trends of note. One is that people with private insurance more likely to complete the series than those with public insurance. Economically disadvantaged females also completed the series at a lower rate than those at or above the poverty level. The racial and ethnic disparities also exist, where Whites are more likely to complete the vaccine series than African Americans or Hispanics. The study by Chao, et al. investigating motherdaughter pairs also showed similar results to the initiation arm, except that African American mothers with a history of STI had daughters that were less likely to complete the series, but
Asian mothers with a history of STI had daughters that were much more likely to complete the series.
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Study Quality:
The cross-sectional studies have the greatest potential for confounding and temporal effects.
Many of the studies suffered from small sample sizes, large chunks of missing data, and poor generalizability. A summary of the major potential sources of bias in each study are shown in Table 3 . 
Chao, et al (2)
A lot of missing data for race/ethnicity (50%). No mention of sample size in Logistic Model
Chao, et al (3)
A lot of exclusions limit generalizability, used census data to indicate SES. Also used pap test history as a surrogate for mom's view on vaccination, which is not an accurate representation of vaccine attitudes. No mention of sample size in logistic model
Conroy, et al
Small sample, limited generalizability (hospital setting), short interval between recruitment and study.
Dempsey, et al (1)
Small sample with respect to completion, limited generalizability (university health system), no women over age 18, no subjects without insurance.
Dempsey, et al (2)
Hard to generalize, used a hypothetical vaccine scenario. Survey had fixed responses which could bias answers. Response bias.
Jain, et al
Small sample (only 168 women), no females younger than 18 years old, a crosssectional design, subject to recall bias and non-response bias. Administered soon after approval, early in the process.
Kahn, et al
Small sample, subject to selection bias and also did not have vaccine availability in clinics. No absolute numbers reported, only percentages. The table below summarizes each study's quality. Each study was evaluated based on an appraisal scheme outlined in the methods. Many studies had poor generalizability given a limited sample population and age restriction. The cohort studies were either fair or good quality, but most of the cohort studies were limited to one study site or location, 19 and two of these studies were further limited by a small sample size. 18, 21 The exceptions, however, were three studies by
Licht, et al
Chao that included many patients captured from a data repository within a managed care organization in southern California. 17, 20, 22 Nevertheless, the benefit of a large sample size was diminished by the fact the data set had large amounts of missing data and that the study population did not include subjects who lacked insurance or who were on public insurance.
The cross-sectional designs were much more varied in their quality; one was good quality, 28 four were fair quality, 23-24, 26, 30 and three were poor quality. 25, 27, 29 Although poor quality studies were included in this review due to the paucity of literature on the subject, their results need to be cautiously interpreted given how fraught they are with flaws. For example, the study by Patel was only a published abstract with no corresponding full manuscript in publication, which gives the audience no idea about its quality or its methods. 27 Another study assessed vaccination rates in clinics where the vaccine was unavailable for parts of the study period, which has the potential to greatly affect the outcome in question. 25 The rest of the cross-sectional studies were mainly limited by the lack of response from survey participants, which might lead to a response bias. 
Discussion
Summary of Evidence:
Overall, the evidence is too heterogeneous for the data to be combined in a meta-analysis.
Nevertheless, the studies themselves point to a HPV vaccine initiation rate between 25-45%, depending on the specific patient population (11-12 year olds or 18-26 year olds for example).
This number is likely to increase over time as the vaccine becomes more established within the medical system and becomes more accepted as a safe and efficacious option against cervical cancer. The vaccine completion rates also varied greatly, but most studies indicated a completion rate (sampling only from a group that initiated) between 40-50%. The overall completion rate, which refers to the number of females who completed the vaccine series out of the entire group of eligible subjects (not just the ones who initiated), ranged between 15-18% in two studies. 19, 30 When discussing correlates for vaccine initiation or series completion, many studies employed varied statistical methods to find significant predictors, such as a log-log binomial regression model, logistic regression, or simple bivariate analyses. Given the different methods, the outputs were different as well; some studies used risk ratios, others used odds ratios, and some used percentages. While it is difficult to compare the numbers, the conclusions were similar across all studies. Vaccine initiation and completion are associated with covariates like age, race, ethnicity, insurance type and status, socioeconomic status, normative beliefs about the vaccine, a mother's pap smear history, and discussion with a physician. Some studies found that economically disadvantaged females or minorities like Hispanics or African Americans had paradoxically higher rates of vaccine initiation, but that may be due to the fact that economically disadvantaged patients have access to the Vaccines for Children program and do not have to face the financial barrier of paying for the vaccine that some privately insured patients face. The majority of African-Americans and Hispanics in some of these studies were also below the poverty level -which might indicate that the higher vaccination initiation rates might be due to socioeconomic factors rather than racial factors. 19, 30 When looking at completion rates, however, private insurance and White race become predictors for completion, which then indicates that there might be some differences between getting a patient to initiate the vaccine and having them return for the 2 nd and 3 rd visit to complete the series.
It is quite difficult for a clinician to apply the literature known about HPV vaccine to his or her patient population since each study has a specific target patient population (limited by age range, practice location, and insurance status), and has limitations that impair its generalizability (poor study design, lack of adequate follow-up, or even lack of vaccine availability during the study period). Thus, a study with a larger, representative sample of patients with enough follow-up periods to adequately capture enough data for completion rates and factors associated with those is needed. While three of the studies also looked at on-time dosing rates, they were not explicitly discussed and had no correlates for on-time dosing either.
Limitations:
At the outcome level, the main limitation of trying to compare each of the studies is that the patient population and follow-up periods are not the same across studies. Various studies had shorter follow-up times which would decrease completion rates, and furthermore, the different patient populations studied might also lead to systematic differences in vaccination rates and correlates for uptake or completion. This makes it hard to make generalizable statements when pooling the outcomes. Furthermore, some studies measured completion rates of the HPV vaccine relative to the entire study population while other studies measured completion rates within a cohort of patients that initiated the vaccine. Therefore, it is difficult to compare completion percentages without knowing the absolute numbers, and some studies did not provide the number of patients that initiated the vaccine.
At the study level, many of the studies had limitations due to small sample size, missing data, or weak study design. A lot of the studies were cross-sectional surveys, which subjects the results to recall bias and non-response bias. Furthermore, although a cross-sectional survey design is good for detecting prevalence of a condition (such as vaccine uptake), it cannot appropriately address vaccination completion rates, given that completion of the series is timedependent; some females who would complete the series might not be captured with a survey at that moment in time. The cohort studies (retrospective or prospective) were limited by missing data (2 studies), a small sample size (2 studies), and limited generalizability due to a selective patient population (4 studies). Many studies also used logistic regression models to find significant predictors of vaccine initiation or completion. Very few of these studies, however, reported about the sample sizes used in the models, and what impact missing data had on the study results.
Conclusions:
The quadrivalent HPV vaccine has only been available for a short period of time (less than 4 years). There have been no systematic reviews attempting to document the national rate of vaccine initiation or completion. When discussing HPV vaccine initiation and completion rates, one of the most widely quoted studies is the CDC report about vaccination coverage among adolescents aged 13-17 years in the US. 30 This phenomenon may be due to its governmental affiliation, national sample, and recent publication, but the study is limited by its methods (telephone survey) and its low response rate (58.7%). Furthermore, they did not have enough data to make conclusions about 2007 completion rates. Nevertheless, initiation rates around 37%
and completion rates of 17.9% (but 41.8% of those that initiated) in 2008 have been cited by many studies as truly representative of the national rate.
Thus an implication for future research would be to update the literature using more current data about the HPV vaccination rates. A study with a longer follow-up period could also increase the robustness of the results and the use of a more inclusive study population (i.e. using 9-26 year olds instead of 13-17 year olds) would yield more generalizable results as well. Lastly, a study investigating the rates of on-time dosing would be helpful given the paucity of data on the subject. Given the fact that there is no evidence regarding the efficacy of the HPV vaccine with a delayed dosing schedule or an incomplete dosing regimen, knowing the prevalence of both problems might be informative for development of interventions to boost vaccination rates if future studies do show a decrease in efficacy given poor adherence to the recommended dosing schedule or incomplete vaccination.
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Introduction:
The human papillomavirus (HPV) infects an estimated 6.2 million people in the United
States every year, making it the most commonly sexually transmitted infection (STI doses. 8 Furthermore, adherence to the recommended dosing intervals is likely to be poor among adolescents. [10] [11] [12] A few studies have examined correlates for completion of the HPV vaccination series.
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However, we are not aware of any studies documenting factors associated with on-time dosing in addition to vaccine series completion. Therefore, the goal of this study was to measure the rates of HPV vaccine series completion and on-time dosing based on the recommended schedule among those who initiate the series, along with factors associated with series completion and ontime dosing. This information may be helpful in developing strategies to increase on-time completion of HPV vaccination among adolescent girls.
Methods:
Study Design
This retrospective cohort study was a secondary data analysis of computerized immunization records in the state of North Carolina. The study protocol was submitted to the Duke University Health System Institutional Review Board (IRB) and exempted from full review.
Data Source
The North Carolina Immunization Registry (NCIR) is a statewide database containing information on immunizations delivered in all the health departments and more than 600 private practices throughout the state. As of 2009, 72% of public providers and 61% of private providers used the registry to record immunizations. A public provider is defined as a public health department, a community/migrant health/rural health clinic, Indian health service clinic, or any public clinic that provides immunizations, such as a publically funded non-profit neighborhood clinic. A private provider is defined as a private health plan, group of doctors, or clinic that is not a federally qualified health center (FQHC). For each individual included in the dataset there are fields for the person's county of residence, race, ethnicity, and each vaccination date. For every individual vaccination date the recipient's age, clinic type, and funding source for the vaccine could also be entered.
Study Population
Our study sample consisted of all females whose immunization information was included in the NCIR and who received at least one dose of the HPV vaccine series of which the first dose 
Variables
The main outcomes were completion of the HPV vaccine series and on-time completion of the vaccine series. Completion of the series was defined as documentation of at least 3 separate HPV vaccine doses. On-time completion was assessed by the intervals between the three doses.
An on-time dose was defined as 2 ± 1 months (28-84 days) between the first two doses and 6 ± 2 months (112-224 days) between the first and third doses as outlined by the HPV4 package insert. 13 This dosing window was used since studies by Merck have shown no reduction in immunogenicity with the aforementioned schedule flexibility.
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The exposure variables examined were: race, ethnicity, age, county of residence, the clinic type, and funding type. Race was categorized as American Indian/Alaska Native, Asian, Black/African-American, Native Hawaiian/Pacific Islander, Other, or White. Ethnicity was divided into Hispanic or non-Hispanic. Clinic type (Family, local health department, hospital, internal medicine, juvenile corrections, K-12 school, university/college, pediatrician, or other), source of funding (public or private), and age (in months) of the recipient were listed for each vaccine dose. Each variable was not self-reported, but rather manually entered for each entry by the provider using the registry.
Data Analysis
We used means or proportions to describe the characteristics of the girls and young women in the sample. We examined factors associated with series completion as well as on-time dosing using unadjusted bivariate analyses and tested for significance using Pearson's chi-squared test.
We used logistic regression to examine the independent effects of the exposure variables on series completion and on-time dosing. The subjects were categorized into three age groups, 9-12 years of age (young girls), 13-17 years of age (adolescents), and 18-26 years of age (young women), in order to compare the differences among age groups with regards to vaccination completion and on-time dosing. Counties were classified as metropolitan statistical areas based on US census data. 31 For the logistic regression analysis, age, funding source and clinic type were based on the first dose of the vaccine. We used listwise deletion to handle missing data.
This method of logistic regression ignores all entries with missing data and only uses entries with a complete set of variables in the analysis, which yields a complete-case analysis. To examine the effect of missing data, we created a regression model with dummy variables for all unknowns and compared it to the complete-case analysis. All p-values were considered significant at ≤ 0.05 and 95% confidence intervals were reported when appropriate. Stata Version 11.0 (Statacorp, College Station, TX) was used for all analyses.
Results
Characteristics of the Study Population
The girls and young women in the cohort were mainly White (63%) and non-Hispanic (91%) ( 
Completion Rates and On-Time Dosing
Of 
Factors Associated with Vaccine Completion and On Time Vaccine Dosing
Vaccine series completion and on-time series completion varied significantly with race (p<0.001 for both) with Whites more likely than Blacks to complete the series (59% vs. 43%) as well as complete the series on-time (55% vs. 43%). Non-Hispanics were also more likely than
Hispanics to both complete the series (54% vs. 46%, p<0.001) and do so on-time (51% vs. 47%, p<0.001).
Both those 9-12 years of age and 13-17 years of age had similar completion rates (57%) that were higher than those 18-26 years of age (42%). Nevertheless, when comparing on-time dosing rates, of those 18-26 years of age who completed the series 55% did so on-time, compared with approximately 50% of those 9-12 years of age and 51% of those 13-17 years of age. Compared to those whose vaccine was publically funded, the girls and young women whose vaccine was funded by private insurance were more likely to complete the series (61% vs. 46%, p<0.001 and do so on-time (54% vs., 47%, p<0.001)
Completion and on-time dosing rates differed by the type of health care clinic from which the girls and young women received immunizations. Those vaccinated at pediatric clinics had the highest completion rates at 61%, followed by those vaccinated at family medicine practices at 53% and those vaccinated at local health departments at 39%. For on-time dosing, girls and young women vaccinated at family medicine practices had the highest rate at 56%, while those vaccinated at pediatric clinics or at local health departments had on-time dosing rates at 50%.
Of those who completed the series (n = 76,491), the vast majority (96.1%) stayed with the same clinic, and 52% of them completed the series on-time. Only 28% of those who switched clinic type, however, completed the series on-time. Additionally, 85% (47,802 / 56,389) of females who completed the series stayed with the same funding source, and 52% of them completed the series on-time. Among those who switched funding sources, 47% completed the series on time.
Independent Associations with Vaccine Completion
Compared to Whites, African-Americans were less likely to complete the series (OR 0.55; 95% CI 0.53 -0.56) as well as complete it on-time (OR 0.66; 95% CI 0.64 -0.69) ( Table 3) The results for the logistic regression model using a complete-case analysis are similar to the model with dummy variables for unknown data, except that local health departments and Hispanic ethnicity became statistically insignificant for on-time dosing. For series completion, age (9-12 years) also became insignificant.
Discussion
Using a large statewide database, we found that after three years of availability on the market, completion of the HPV vaccine series among those who initiate it is low (overall 55%), and on-time dosing of the vaccine is even lower (overall 28%). When examining completion rates stratified by the year the patient initiated the vaccine, the percentage of those completing the series increased steadily over time (32% after one year to 84% after three years). Most of the girls and young women completing the vaccination series, however, did so within one year (82%). The percentage of those completing the series on-time, however, has decreased from 43%
of those who initiated the series in 2006 to 25% for those who initiated in 2009. This likely means a sizeable majority of those who started the series will complete it, but not on-time.
African Americans and Hispanics were less likely to complete the series and receive all doses on-time compared to Whites and non-Hispanics. Furthermore, private funding for the vaccine was associated with higher odds of completion and on-time dosing compared to public funding.
These results are in agreement with previous studies about HPV vaccination completion, which also found that African Americans and those on public health insurance were less likely than those of other races or those with private health insurance to complete the series. [17] [18] [19] 30 Studies examining factors associated with reduced vaccine series completion have shown mixed results 19, 30 . 20, 26 Differences may be secondary to the vast differences in study population demographics. Nevertheless, the results from our study indicate that the rates of completion of the series as well as on-time dosing of the three doses differ across racial and socioeconomic groups, a finding that is consistent with the few existing studies investigating correlates for completion (and not initiation).More work is needed to develop and test interventions or programs that aim to eliminate disparities in vaccination rates.
We found the factors associated with series completion and on-time dosing to be similar but not identical. For example, our data suggest that young women (18-26 year olds) are much less likely to complete the series than the adolescents(13-17 year olds), but of those who do, are more likely to complete it on-time. Our results are in agreement with other studies that have shown that college-age women are much less likely to initiate the vaccine than younger girls. [20] [21] 26 This finding might be due to the fact that young adult women are not covered under the Vaccine for
Children Program, or they might have lost insurance previously provided by their parent's private coverage. Nevertheless, the observation that of those who do complete the series, those in the adult age range are more likely to complete it on-time may be due to their ability to have a more flexible schedule than younger girls. Furthermore, compared to younger women, older women may exhibit more health care seeking activities and hence have more opportunities for HPV vaccination. One such example is the pap test, which has been shown in one study to be a predictor of HPV vaccination amongst daughters of mothers with a history of regular pap smears. 22 Our result, however, is in contrast to one other study by Chao, et al., which found that those aged 18-26 years old had higher vaccination completion rates than younger girls aged 9-17 year old (47.1% versus 41.9%). 17 This latter study was limited by a fairly small sample in the older age group and only looked at women within a managed care organization which eliminates observed differences in insurance coverage between older women and younger girls as a potential barrier to vaccination completion.
With regards to clinic type, patients of who saw providers at pediatric clinics were more likely than those of at family medicine practices and local health departments to complete the series. This finding is in contrast to that in a study by Chao, et al., which stated that patients of pediatricians had lower completion rates than patients of family medicine or internal medicine physicians. 17 The study populations between our study and the study by Chao, et al., are very different, but the reason for the contrasting results between studies is unclear. Patients immunized by providers at K-12 schools were much more likely to complete the series and complete the series on-time than those seen at pediatric clinics, but the results need to be tempered by the fact that this subgroup had a relatively small sample size (n = 244). Larger samples need to be gathered before these results can be assuredly generalized to the external source population, but these results are in agreement with other studies that have shown that school-based vaccination programs are effective at series completion. 32 Studies have shown that physician recommendations are very important in determining vaccine uptake, 29, 33 and thus any differences in clinic type vaccination rates may be due to the differences in acceptability of the vaccine amongst providers. [34] [35] If that is the case, interventions targeted at improving provider acceptance of the vaccine as well as improving provider recommendation of the vaccine to the target population (ideally females 11-12 years of age) would increase vaccination rates. 36 Living in a rural area (non-Metropolitan Statistical Area) was statistically significantly associated with increased completion and on-time dosing rates, but the clinical importance of such a result is not compelling. This is in agreement with other studies which found that distance from a clinic was not associated with differences in completion rates. 18 The differences among county vaccination rates are probably due to differences in area poverty and socioeconomic status rather than rurality, as shown by one study looking at HPV vaccination rates and geographic disparities. 37 
Strengths and Limitations
One of the strengths of the study is the data source: the North Carolina Immunization
Registry (NCIR), based on the Wisconsin Immunization registry, is a well-validated and robust
Immunization Information System that satisfies the 12 minimum functional standards developed by the CDC. 38 The most current numbers suggest that the NCIR has strong penetrance among the providers in the state; as of 2009, 61% of private providers and 72% of public providers (including all local health departments) were using the registry to record immunization records (personal correspondence, 2010). It is also a large repository of data; 138,823 separate patients were used for analysis, which makes the results very robust. Furthermore, the patient sample is diverse, which allows for more generalizable results. Nevertheless, the registry is only robust if the data entry is complete. Inconsistencies in how each practice records its immunizations, systematic differences between practices inside the registry from those outside the registry, and the migration of people in and out of the system will make it more difficult to generalize the results from this study.
The biggest limitation to this study was the large proportion of entries with some missing data. Many entries were missing data about race, ethnicity, funding source, and county of residence. This limited the number of females available for analysis using the regression model, but the logistic model utilizing dummy variables for unknown values did not change the results drastically, which is reassuring to the validity of the results, even with missing data. Multiple imputation was considered as a method to evaluate the effect of missing data on the outcomes.
However, the dataset had limited variables from which we could draw upon for imputation of all the missing data. Also, we were uncomfortable with the assumption that variables were missing at random, and were not willing to impute race (and other missing variables) based on the outcome, which we would then use to make conclusions about the associations between these exposures and the outcome. Thus we decided to compare the complete-case analysis and a model using all entries with dummy variables for unknown values.
Conclusions and Implications
Among girls and young women who initiate the HPV vaccination series, overall completion rates are low, but given enough time (three years), most of those who begin the series will complete it. On-time dosing rates, however, are declining, and have been hovering at 25% for the past two years. The significance of delayed dosing with respect to vaccine immunogenicity and vaccine effectiveness are not well defined.
Additional studies are currently underway to assess how the late timing of the intervals between the doses affects the humoral immune response. [13] [14] [15] [16] The factors associated with completion and on-time dosing are similar. African-American race, Hispanic ethnicity, and having public insurance are associated with reduced series completion and on-time dosing.
Efforts are needed to eliminate disparities in HPV vaccine delivery. Finally, if future research shows that delayed dosing leads to reduced vaccine immunogenicity, then new vaccines with reduced dosing requirements or strategies designed to improve on-time vaccine delivery will be needed. Females who received 3 doses Figure 1 . The pie graph on the left indicates the proportions of females aged 9-26 years of age receiving differing numbers of doses of HPV vaccine. The pie chart on the right displays the proportions of females who completed the series that received all three doses on-time or not ontime.
